| Hans-Günter Meyer-Thompson | Naloxon
USA. FDA Exempts Harm Reduction From Biggest Naloxone Access Restrictions
USA. FDA Exempts Harm Reduction From Biggest Naloxone Access Restrictions
On September 22, the Food and Drug Administration announced that harm reduction naloxone suppliers are exempt from wholesale pharmaceutical distribution restrictions, effective immediately. This de facto waives naloxone’s prescription requirement at the federal level, allowing the broader harm reduction community to purchase and distribute naloxone in bulk for the first time. (FILTER, USA, 26.09.2022)